obstructive sleep apnea, FDA

FDA approves anti-obesity drug as first sleep apnea medication
The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment of the disorder.
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.
Suffer from sleep apnea? The first FDA-approved medication could help
For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday statement from the Centers for Medicare & Medicaid Services comes after Zepbound in December became the first drug approved in the U.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Lilly's Zepbound to be covered by Medicare for sleep apnea
Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep apnea in people with obesity. CNBC said Wednesday that the U.S. Centers for Medicare & Medicaid Services confirmed that Medicare drug plans can now cover Zepbound,
BioSpace1d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
STAT11d
Extending Medicare coverage to obesity medications is imperative
Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...
Wegovy to Zepbound: The Pros and Cons of Weight Loss Medications
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
health.wusf.usf.edu12d
FDA declares the shortage of obesity drug Zepbound has ended. The results are complicated
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
Yahoo Finance7d
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs. Also Read: US Employer Health Costs To Rise In 2025 Fueled By Weight Loss ...
Onlymyhealth10d
FDA Approves Weight-Loss Drug Zepbound For Obstructive Sleep Apnea
The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.
San Diego Union-Tribune9d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The FDA first approved Zepbound to treat obesity ... Medicare does not cover weight-loss drugs specifically for obesity, although the medications can be covered for conditions exacerbated by ...